1006-08-2

Basic information

• Product Name: 6-HYDROXY-7-METHYLPURINE
• Synonyms: 7-METHYLHYPOXANTHINE;6-HYDROXY-7-METHYLPURINE;6H-Purin-6-one, 1,7-dihydro-7-methyl- (9CI);(6S)-3-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R,5R)-4,5-dihydroxy-2,6,6-trimethyl-1-cyclohexenyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-6-hydroxy-2,4,4-trimethylcyclohex-2-en-1-one;7-methyl-3H-purin-6-one;7-Methyl-7H-purin-6-ol
• CAS NO: 1006-08-2
• Molecular Formula: C₆H₆N₄O
• Molecular Weight: 150.14
• Product Categories: PYRIMIDINE
• Mol File: 1006-08-2.mol

Chemical Properties

• Boiling Point: 447.3°Cat760mmHg
• Flash Point: 224.3°C
• Appearance: /
• Density: 1.6g/cm³
• Vapor Pressure: 3.41E-08mmHg at 25°C
• Refractive Index: 1.772
• CAS DataBase Reference: 6-HYDROXY-7-METHYLPURINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-HYDROXY-7-METHYLPURINE(1006-08-2)
• EPA Substance Registry System: 6-HYDROXY-7-METHYLPURINE(1006-08-2)

Safety Data

• Hazardous Substances Data: 1006-08-2(Hazardous Substances Data)

Usage

Uses

Used in Biochemical Research:
6-Hydroxy-7-methylpurine is used as a research compound for studying its structure, properties, and biological roles in biochemical and pharmacological contexts. Its involvement in DNA repair mechanisms and potential harmful effects when accumulated excessively make it an important subject for understanding metabolic pathways and developing therapeutic strategies.
Used in Drug Development:
6-Hydroxy-7-methylpurine can be utilized as a starting material or intermediate in the synthesis of pharmaceutical compounds targeting DNA repair mechanisms or other related biological processes. Its unique structure and properties may offer novel therapeutic opportunities in the treatment of diseases associated with DNA damage or repair deficiencies.
Used in Diagnostic Applications:
Due to its role in DNA repair mechanisms, 6-Hydroxy-7-methylpurine may be employed as a biomarker or diagnostic tool for assessing the status of DNA repair pathways in various diseases or conditions. Monitoring its levels or activity could provide valuable insights into the health of an individual's DNA repair mechanisms and potential risks for certain diseases.

InChI:InChI=1/C6H6N4O/c1-10-3-9-5-4(10)6(11)8-2-7-5/h2-3H,1H3,(H,7,8,11)

Upstream product

• 33763-06-3 7-methylinosine 
• 4261-05-6 4-amino-1H-imidazo<4,5-c>pyridine hydrochloride 
• 3641-08-5 1,2,4-triazole-3-carboxamide 
• 87-42-3 6-chloropurine 
• 5440-17-5 6-chloro-7-methyl-7H-purine 
• 191416-90-7 4-formamido-N'-methoxy-1-methyl-1H-imidazole-5-carboxamidine 
• 52376-64-4 N⁶-methoxy-7-methyladenine 
• 115377-71-4 4-amino-1-methyl-1H-imidazole-5-carboxamide perchlorate 
• 68-12-2 N,N-dimethyl-formamide 
• 77287-34-4 formamide 
• 110475-17-7 5-amino-3-methyl-3H-imidazole-4-carboxylic acid amide; hydrochloride 

Downstream Products

• 3324-79-6 7-Methyl-6-thiopurin 
• 5440-17-5 6-chloro-7-methyl-7H-purine 

Relevant articles and documents

Purines. LIX. An alternative synthesis of 7-alkyl-1-methyladenines by regioselective alkylation, fission, and reclosure of the adenine ring

7-Alkyl-1-methyladenines (12a,b) have been synthesized from 1-alkyl-4- aminoimidazole-5-carboxamides (5a,b) in two steps [hence from adenine (1) in six steps]. The synthesis started with dehydration (using POCl3-HCONMe2) of 5a,b, rea

OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

NEW TRPA1 ANTAGONISTS

The present invention relates to bicyclic heterocyclic derivatives of Forrmula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by TRPA1 channel inhibition or antagonism.

Regioselective and efficient synthesis of N 7-substituted adenines, guanines, and 6-mercaptopurines

A simple and efficient protocol for the preparation of N 7-substituted adenines, guanines, and 6-mercaptopurines is described. The key step is the regioselective preparation of 7-substituted 6-chloropurines which are building blocks for the div

Purines. LXXV. Dimroth rearrangement, hydrolytic deamination, and pyrimidine-ring breakdown of 7-alkylated 1-alkoxyadenines: N(1)-C(2) versus N(1)-C(6) bond fission

On treatment with boiling H2O for 5-6h, 1-alkoxy-7-alkyladenines (13) underwent hydrolytic cleavage of the N(1)-C(2) and the N(1)-C(6) bonds to produce the imidazole-5-carboxamidines (14) in 53-60% yields and the imidazole-5-carboxamides (18) i

Deribosylation of Mesoionic Nucleosides in the Reaction with Lithium 2-Methylpropane-2-thiolate

A series of mesoionic nucleosides related to 7-methylguanosine (I) was subjected to the action of a strong nucleophilic reagent, lithium 2-methylpropane-2-thiolate.Nucleophilic displacement of the β-D-ribofuranosyl portion appeared to be the main direction of the reaction.No dealkylation products were found in the reaction mixtures.